📄 Direct examination of Gary Sims (part 5) — Tuesday, May 16, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\16\DIRECT-EXAMINATION-OF-GARY-SIM.DOC
TRIAL
▲ Day 75 of 167

Direct examination of Gary Sims (part 5)

Witness: Gary Sims
Examiner: Rockne Harmon
Called by: Prosecution • Date: Tuesday, May 16, 1995 • Utterances: 144
Gary Sims continued his direct examination with Rockne Harmon, covering the scope of DOJ's DNA testing (approximately 108 samples), which items were fully consumed during testing, and the availability of remaining DNA for potential retesting. The bulk of the session was a technical tutorial on RFLP vs. PCR methodology, laboratory controls, extraction procedures, and how the DOJ lab's approach compares to Cellmark's and the FBI's.
1 (The following proceedings were held in open court:)
2 MR. HARMON:

Mr. Sims, what is total number of items, including substrate controls, that your lab tested in any way?

3 MR. SIMS:

This would be the number of items that we actually extracted. Something like 108 samples, including the substrate controls.

4 MR. HARMON:

Okay. And--rather than go item by item on what was conserved, to speed things up, can you tell us of those items, how many of those items were actually totally consumed in the testing?

5 MR. SIMS:

Yes, I can tell you that. I need a moment to count, but I can tell you that fairly quick.

6 THE COURT:

I think we need to know which ones, not just the number.

7 MR. HARMON:

When you give us the number, if you could identify the items, too.

8 (Brief pause.)
9 MR. SIMS:

The items that--these are the ones where we consumed the sample. This would be item no. 113, which relates to a hair.

10 MR. SCHECK:

Are these your numbers or LAPD numbers?

11 MR. SIMS:

These are LAPD numbers. Okay. So that was item no. 113 which relates to a hair. Item no. 115, I think that is one of the rear gate bloodstains. Item no. 116, a second rear gate bloodstain. I believe that is it. I think even on the glove and the sock there were still some traces I know in those general areas that we sampled. There was one area on the glove that we thought was tissue that that was consumed.

12 MR. HARMON:

Okay. And that proved not to be tissue; is that true?

13 MR. SIMS:

On the glove it indicated to me that it was tissue.

14 MR. HARMON:

I'm sorry. In addition to--these are actually the swatch items or the initial evidence items. In addition to those items, was there--is there also extracted DNA left over from many of these items?

15 MR. SIMS:

Well, yes. Most of those items there are--there is extracted DNA and for example, when I mentioned 115 and 116, those are those rear gate samples, there is extracted DNA from those left over. I think we mentioned the hair--the hair we haven't talked about earlier, but that work was done by Stephen Meyers in our laboratory and he did not detect any DNA in that extract, so that extract still remains. We didn't do my typing of that sample.

16 MR. HARMON:

Okay. And as an example of what one can do with extracted DNA, is that what you sent to cellmark for their analyses on 13a1, the cutting from the sock?

17 MR. SIMS:

That would be an example of that sort of approach.

18 MR. HARMON:

And 29, the steering wheel stain?

19 MR. SIMS:

Yes.

20 MR. HARMON:

And 84, the three nail kit items?

21 MR. SIMS:

Yes.

22 MR. HARMON:

So is it possible to--to do additional testing with that extracted DNA if one were to try to confirm results?

23 MR. SIMS:

Certainly.

24 MR. HARMON:

And in addition to extracted DNA, is there also something--the jury has heard from Dr. Cotton on these processes--amplified DNA that is as a result of the PCR process after DNA is amplified?

25 MR. SIMS:

Yes. On most--almost all of these samples, in fact, there should be amplified DNA left over that is now residing in our PCR product room.

26 MR. HARMON:

And as a forensic scientist do you feel that the best check on your analytical reliability is reanalysis of the evidence?

27 MR. SCHECK:

Objection.

28 THE COURT:

Sustained.

29 MR. HARMON:

Do you feel that it is possible--

30 MR. SCHECK:

Objection again.

31 THE COURT:

Sustained. Why don't you rephrase the question.

32 MR. HARMON:

Sure. What could be done with you--as a forensic scientist you have got considerable experience before you worked for DOJ. What could one do with remaining swatch, let's say, from the same item.

33 MR. SCHECK:

Object to this whole line of questioning.

34 THE COURT:

Overruled.

35 MR. HARMON:

What could one do with a remaining swatch, some extracted DNA and some amplified DNA?

36 MR. SCHECK:

Objection, not specific.

37 THE COURT:

Overruled.

38 MR. SIMS:

Well, let's--

39 THE COURT:

You can answer the question?

40 MR. SIMS:

Let's work backward. With the amplified DNA one has the PCR product already to go, so one could actually test that. To me that is probably not the most useful. Then the next approach would be to look at the extracted DNA and one could take that DNA and either run it through the same types of tests that we ran in our laboratory or run it in an additional genetic marker DNA test to gain more genetic information about a particular sample. Then one takes a further step back to the actual raw sample, the raw swatch itself, and certainly one can do one's own extraction and work on that material.

41 MR. HARMON:

And is that just your opinion or have you relied on the opinions of others in the forensic science field?

42 MR. SCHECK:

Objection.

43 THE COURT:

Sustained.

44 MR. HARMON:

Have you relied on any published literature in that?

45 MR. SCHECK:

Objection.

46 THE COURT:

Sustained. Let's move on in this area. You have established that it is available for other corroboration.

KEY QUOTE
47 (Brief pause.)
48 MR. HARMON:

All right. Mr. Sims, we have covered how you sample and evaluated some but not all of the items. I would like you to explain your problem solving approach. Your lab provides both RFLP and PCR services; is that true?

49 MR. SIMS:

Yes.

50 MR. HARMON:

And for example, when this case was submitted to you with the first batch of stains, what was your initial plan to--what sort of test did you want to perform on those stains?

51 MR. SIMS:

Well, initially we thought this might be an RFLP case all the way and our initial involvement in this case was very limited. If you would like I can go into a little bit of that history.

52 MR. HARMON:

That is okay. Is that okay, your Honor? Go ahead.

53 THE COURT:

No, I don't want to hear history; I want to hear facts.

54 THE COURT:

All right. The initial testing plan was RFLP. Apparently that didn't happen.

55 MR. HARMON:

Okay.

56 MR. SIMS:

Yes. Initially we were planning to look at a very few number of samples to do RFLP testing in this particular case. As it turned out, some of those initial samples turned out to be in a degraded state and not suitable for RFLP analysis and in particular that would be the Bundy drops that--that we looked at in that initial series.

57 MR. HARMON:

So is it fair to say that RFLP would have been the preferred approach if there was enough DNA and it was intact?

58 MR. SIMS:

Yes, I think so, because the RFLP test is more discriminating. You have a much better chance of excluding somebody who is not really the source of those samples.

59 MR. HARMON:

And at what point do--do these samples actually flow through the same possess in the beginning and then branch out, depending on how much DNA and how intact it is?

60 MR. SIMS:

Yes. What we do is we do the initial extraction of the sample and then we evaluate to see whether or not we should proceed with the RFLP or the PCR approach.

61 MR. HARMON:

Do you use the same extraction technique for both methods?

62 MR. SIMS:

Yes. In our laboratory we do. The type of extraction we do is designed so that we can use that DNA either for PCR or for RFLP, which is different than some laboratory's approach.

63 MR. HARMON:

For example, cellmark, do you know what they do with PCR?

64 MR. SIMS:

I don't have a real clear idea on what they are doing. They may do chelex type extractions. I think LAPD does chelex extractions also.

65 MR. HARMON:

All right. So at some point you reach a fork in the road and choose RFLP or PCR?

66 MR. SIMS:

That's correct.

67 MR. HARMON:

Okay. Do you have written protocols in your laboratory for performing RFLP in your lab?

68 MR. SIMS:

Yes, we do.

69 MR. HARMON:

Are those protocols based on the scientific literature?

70 MR. SIMS:

Yes, they are.

71 MR. HARMON:

Are there a number of ways to perform RFLP analyses?

72 MR. SIMS:

There are variations on the theme. I mean, it is basically the same--the same process but different laboratories use, for example, different restriction enzymes. That is the enzyme that shoots in at a specific site. And also different laboratories use different probes to look at different sites of genetic variation in the DNA.

73 MR. HARMON:

Okay. If you will, can we just compare the system that you have with the system in place at the FBI. Are you familiar with that?

74 MR. SIMS:

Yes, I am.

75 MR. HARMON:

And how does your system compare with the FBI's system?

76 MR. SCHECK:

Your Honor, I think there is a relevancy problem on this.

77 THE COURT:

Sustained.

78 MR. HARMON:

Can I make--there is--it relates back to databases, your Honor.

79 THE COURT:

All right. Let me see counsel at the side bar with the court reporter.

80 (The following proceedings were held at the bench:)
81 THE COURT:

We are over at the side bar. What is the relevance of comparison?

82 MR. HARMON:

Well, briefly, they have used the same restriction enzyme and data can be interchanged between the two and we have already had a reference to that much earlier on on compatibility of databases. That is one of the articles that Mr. Sims talked about of his qualifications.

83 MR. SCHECK:

I have no objection to him saying that they used the same restriction enzyme. I have a lot of problem if he is going to be qualified an as a population geneticist to talk about the appropriateness of using different databases. I don't think he is qualified to do that.

84 MR. HARMON:

That wasn't the question. Are they compatible systems?

85 THE COURT:

All right. The objection is overruled.

86 (The following proceedings were held in open court:)
87 THE COURT:

Thank you, counsel. Proceed.

88 MR. HARMON:

Very briefly, Mr. Sims, what is the compatibility or the similarity of the system in place at DOJ lab versus the FBI and many other labs in this country?

89 MR. SIMS:

The main point is that we use the same restriction enzyme which is called hae-3, h-a-e-3, and also that we use the same probes, there is a battery of probes that overlap, and we have exchanged samples with the FBI to show that our data is compatible with their data.

90 MR. HARMON:

Okay. And if you would, would you contrast the system that you use and the FBI and many other labs with Cellmark's because the jury has heard quite a bit of Cellmark's approach to RFLP.

91 MR. SIMS:

Yes. The main difference is that they are using a different restriction enzyme for their analysis and I believe it is hin-f1 is their restriction enzyme and what it basically does is it gives larger DNA restriction fragments, so their stuff tends to band higher up on these gels that we look at. And I believe two of the probes that we use are the same probes as ours and I think there are three different ones that they also use, but it is the same fundamental process.

92 MR. HARMON:

Now, cellmark has described--Robin Cotton described a cocktail probe which is a mixture of their single locus probes. Do you or the FBI use that same sort of cocktail?

93 MR. SIMS:

We do not and I do not believe the FBI does.

94 MR. HARMON:

Okay. Do you have controls built into your RFLP testing to measure how well the test has been performed in any given test?

95 MR. SIMS:

Yes, we do.

96 MR. HARMON:

Could you briefly describe the types of controls, specifically in the RFLP process, that you have and what their function is.

97 MR. SIMS:

Yes. There are two main controls that we run on the RFLP on any particular autorad that you see. One will be what is called a k562 standard. That is a--a DNA--cell-cultured DNA that is run almost--not in every lab in the nation, but a lot of laboratories in the nation use that as a standard control. We know where the value should be for the two bands or sometimes one band that is produced by that particular standard. And so that provides us important information. It tells us that the probing was working correctly. And the sizing information is also checked that way. The second control that I--and I mentioned this a little bit earlier--was that we always run on an RFLP gel. We always run one of these quality control samples. That is a sample that is unknown to the analyst, and then the analyst goes through and determines what the band sizes are for that particular sample and then submits that data for review, so that is blind to the analyst.

98 MR. HARMON:

Okay. That is--I think you mentioned the supervisor actually looks at what the true values are?

99 MR. SIMS:

Right.

100 MR. HARMON:

And what is--and if there is a discrepancy between the two, what happens?

101 MR. SIMS:

If there is a discrepancy between the two, we have never had one that I know of where we have mixed up anything. We have--I know in my case I had one particular sample where one band, a very high band, was slightly off because of a gel problem and then we rejected that entire data and I reran the entire experiment.

102 MR. HARMON:

Okay. If you would, let's talk about how your PCR process works as opposed to the RFLP process. Just give us a little overview. What sort of markers do you use for PCR and DOJ lab?

103 MR. SIMS:

Yes. The markers that we use for PCR, first off, would be the DQ-Alpha marker and that is the one that has been in most--perhaps the most widespread use in forensic science. It has got a fairly long history now of usage. Then the other--

104 MR. HARMON:

Do you know when that was first used in this country?

105 MR. SIMS:

The first case that I am aware of that that was used in was--it was Dr. Blake who pioneered the use of PCR in forensic science and that would be in 1986, I believe it is People versus Pestinikis, I think it is a Pennsylvania case. I may be wrong on the state.

106 MR. HARMON:

So you have the DQ-Alpha marker?

107 MR. SIMS:

Yes.

108 MR. HARMON:

And Robin Cotton described the type of process that that entails. Do you have an additional PCR marker?

109 MR. SIMS:

Yes. The other PCR marker that we have on line is called D1S80.

110 MR. HARMON:

Can you just briefly compare, contrast the method of testing of DQ-Alpha with D1S80?

111 MR. SIMS:

Yes. The DQ-Alpha involves looking at a particular genetic locus that has variation in the DNA sequence and we can detect that in this typing procedure that we use, so we are actually looking at a little bit of variation in the sequence to detect that polymorphism or different form. On the other hand, the D1S80 is what is called a length polymorphism. It is somewhat like the RFLP procedure in that the different people have different lengths of this repeated sequence of DNA, but it is detected in a completely different manner than the DQ-Alpha is.

112 MR. HARMON:

The jury has heard a great deal of testimony about substrate controls which we will discuss in a little while. Do you normally process substrate controls through the RFLP process?

113 MR. SIMS:

No. Unless one saw that there was a substantial amount of DNA on the substrate control that could be succeeded to RFLP, one would not. They are really for the PCR.

114 MR. HARMON:

Could you expand on that just a bit more.

115 MR. SIMS:

Yes. The--the importance to me of the substrate controls is that that provides not only a way of evaluating the substrate, that the stain is on, whether it be a sidewalk or whether it be a garment or that sort of thing, but it also provides a way of evaluating how a sample is treated through the entire extraction and testing process. I mean, beginning with the scene, taking it all the way through the initial laboratory examination and then following it up with the--with the actual testing and typing procedure. And with PCR one is always on guard for contamination and that is one way of testing to see whether or not there is some contamination.

KEY QUOTE
116 MR. HARMON:

Okay. We will discuss that in a bit. So the substrate controls, if you have them in a given case, are processed through the PCR process from start to finish?

117 MR. SIMS:

Yes.

118 MR. HARMON:

And but not normally in the RFLP process?

119 MR. SIMS:

That's correct.

120 MR. HARMON:

Can you give us any idea of how frequently you do not see substrate controls in cases?

121 MR. SCHECK:

Objection--

122 THE COURT:

Overruled.

123 MR. SIMS:

We generally get them--we generally ask for them from our submitting laboratories, for example, the Bureau of Forensic Services field laboratories will submit substrate controls to us, but at times in my experience with certain types of evidence, one cannot always get a substrate control.

124 MR. HARMON:

So they are great if you have them?

125 MR. SIMS:

Yes.

126 MR. HARMON:

Are there a variety of what is to extract DNA? I think you mentioned the chelex extraction process?

127 MR. SIMS:

Yes. There are a variety of ways to do it. Some of them are just modifications of a theme, but there are different approaches and people have looked at different ways of doing it.

128 MR. HARMON:

Which extraction procedure do you use in the DOJ lab?

129 MR. SIMS:

We use what's called an organic extraction. We actually place the sample into a buffer that contains a soap solution and also an enzyme that chews up protein and that combination loosens up the DNA and gives you what hopefully will be free DNA, because you have to remember that DNA in the cell has protein wrapped around it, and so you have to free the DNA so that you can work with it and that is what the extraction process it.

130 MR. HARMON:

Okay. Do you have a separate written protocol that describes the PCR process, the DQ-Alpha from start to finish?

131 MR. SIMS:

Yes, we do.

132 MR. HARMON:

And yet another separate one for the PCR D1S80 process from start to finish?

133 MR. SIMS:

Yes, we do.

134 MR. HARMON:

Are they based on the scientific literature?

135 MR. SIMS:

Yes, they are.

136 MR. HARMON:

Are these also commercially produced kits that enable you to do these tests?

137 MR. SIMS:

Yes. The DQ-Alpha and the D1S80 are commercially available kits and we use those.

138 MR. HARMON:

Are the protocols that you use ones that you have drafted yourselves?

139 MR. SIMS:

Yes. We look at the protocols that are in existence in the scientific literature and we make some slight modifications of those.

140 MR. HARMON:

Do the manufacturers of these products provide something in addition or something called a user guide?

141 MR. SIMS:

Yes. They provide a user guide that explains some of the parameters of the kits and how they are used.

142 MR. HARMON:

Would this be a good time, Judge?

143 THE COURT:

Perfect. All right. Ladies and gentlemen, we are going to take a 15-Minute recess. Please remember all my admonitions to you and we'll resume in fifteen minutes. And Mr. Sims, you can step down.

144 (Recess.)

Temperature

procedural

Key Quotes (4)

Gary Sims
RFLP would have been the preferred approach if there was enough DNA and it was intact... the RFLP test is more discriminating. You have a much better chance of excluding somebody who is not really the source of those samples.
Sims frames RFLP as the gold standard, implicitly signaling that the degraded Bundy samples — which forced a PCR approach — were a forensic limitation, not a lab choice.
Gary Sims
With the amplified DNA one has the PCR product already to go... Then the next approach would be to look at the extracted DNA and one could take that DNA and either run it through the same types of tests that we ran in our laboratory or run it in an additional genetic marker DNA test to gain more genetic information.
Harmon is laying groundwork that the defense could have requested independent retesting but didn't — a preemptive rebuttal to contamination claims.
Gary Sims
The importance to me of the substrate controls is that that provides not only a way of evaluating the substrate... but it also provides a way of evaluating how a sample is treated through the entire extraction and testing process... with PCR one is always on guard for contamination and that is one way of testing to see whether or not there is some contamination.
Sims defends the reliability of his procedures by explaining how contamination is actively monitored — key to countering defense challenges.
Lance A. Ito
Let's move on in this area. You have established that it is available for other corroboration.
Ito cuts off Harmon's attempt to build further foundation, but the point — that remaining samples exist for retesting — is already on the record.

Evidence (6)

Item 113 (LAPD)
Hair sample — fully consumed during testing; no DNA detected by analyst Stephen Meyers
discussed
Item 115 (LAPD)
Rear gate bloodstain — fully consumed, but extracted DNA remains
discussed
Item 116 (LAPD)
Second rear gate bloodstain — fully consumed, but extracted DNA remains
discussed
Item 13a1 (LAPD)
Cutting from the sock — extracted DNA sent to Cellmark for analysis
discussed
Item 29 (LAPD)
Steering wheel stain — extracted DNA sent to Cellmark
discussed
Item 84 (LAPD)
Three nail kit items — extracted DNA sent to Cellmark
discussed

Notable Exchanges (2)

Rockne HarmonBarry ScheckLance A. Ito
Sidebar over relevance of comparing DOJ/FBI RFLP system to Cellmark's. Scheck argued it was irrelevant and Sims wasn't qualified to opine on database compatibility. Ito ultimately overruled and allowed limited comparison testimony.
strategic
Rockne HarmonBarry ScheckLance A. Ito
Harmon's repeated attempts to get Sims to opine that reanalysis is the 'best check' on reliability were shut down twice by sustained objections, after which Ito stepped in and declared the point established without further foundation questions.
procedural friction

Witness Demeanor

(Brief pause.) — Sims pausing to count consumed sample items before answering

Objections

8 objections (4 sustained, 4 overruled)
Proceeding 6076 • 144 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 16, 1995 📄 Direct examination of Gary Sim
MAY 16, 1995 KRT DvH TD